Hey there, fellow investors! Today, we’re going to peel back the layers on a fascinating company in the biotechnology space: Celcuity Inc. (CELC). This report is all about helping you understand this $4.35 billion company better, exploring its current standing, and looking at where it might be headed. You’re probably wondering, “Is now the right time to invest in Celcuity Inc.?”
That’s a fantastic question, and it’s precisely what we aim to answer. We’ll examine everything from its stock performance and financial health to analyst forecasts and potential risks. It’s about giving you clear, actionable insights, not just a pile of confusing numbers.
CELC Stock at a Glance: Key Insights for Investors
As of November 2025, Celcuity’s stock is trading at $94.00. What’s really catching our eye is its positive momentum; the stock is comfortably trading above both its 50-day and 200-day moving averages. This often signals a healthy uptrend.
Wall Street analysts seem to share a positive outlook, with a 1-year price target of $103.56. That suggests a potential +38.2% upside from current levels, which is quite appealing. However, it’s crucial to acknowledge the significant volatility here, with an annualized rate of 53.4%. This means you should prepare for some potentially wide price swings.
Celcuity Inc. presents a nuanced investment story. On one hand, the company boasts a portfolio of established brands that could drive future growth. On the other, it’s navigating a notable challenge: a high debt load, with a Debt/Equity ratio sitting at 2.74x.
What This Celcuity (CELC) Stock Analysis Covers
We believe in empowering you with comprehensive information, not just simple buy or sell recommendations. This analysis is designed to break down CELC’s stock from every angle, helping you make a truly informed decision.
Here’s what we’ll tackle:
- Is now a good time to buy? Technically, we see a “Neutral” signal, mainly because the Relative Strength Index (RSI) is quite overbought at 93.5. From a fundamental perspective, we’d advise caution, primarily due to current debt levels and certain growth metrics.
- Can its core operations drive future growth? The company’s future growth trajectory will largely depend on the performance of its core Biotechnology operations. Successfully managing competitive pressures in this dynamic industry will also be key.
- What are the biggest risks? Celcuity Inc. carries $320.34 million in debt. This could become a significant headwind, especially in a rising interest rate environment. Moreover, the biotechnology industry is notoriously competitive, with both established giants and nimble new entrants vying for market share.
Forget the jargon-filled reports or overly simplistic “buy this stock” advice. Our goal is to provide you with clear, understandable insights, whether you’re a long-term investor or chasing shorter-term gains. So, is Celcuity Inc. poised to be a success story in your portfolio, or are there hidden issues to be wary of? Let’s dive into the data and find out.
Celcuity (CELC) Stock: Key Metrics & Forecast Summary
Let’s get straight to the numbers that matter most for Celcuity Inc. (CELC). This summary table gives you a quick snapshot of the stock’s current status, key technical indicators, and what analysts are forecasting. It’s a great starting point to gauge the immediate health and future potential of the stock.
| Metric Category | Metric | Value | Notes |
|---|---|---|---|
| Current Price | Live Market Price | $94.00 | As of November 2025 |
| Price Targets & Forecasts | 1-Month Forecast | $94.23 | 📈 +0.2% potential |
| 1-Year Forecast | $129.89 | 📈 +38.2% potential | |
| Analyst Mean Target | $103.56 | 📈 +10.2% potential | |
| Trend & Momentum | Trend | 🚀 ▲ Bullish | Price > SMA 50/200 |
| RSI (14-day) | 93.5 | 🔥 Overbought | |
| MACD | 📈 Bullish Short-Term Trend | 0.77 | |
| Key Technical Levels | Above SMA 50 | ✅ $67.24 | Current support |
| Above SMA 200 | ✅ $38.34 | Long-term support | |
| 52-Week Range | 📏 $7.58 – $98.43 | Significant fluctuation | |
| Volatility | Volatility (30d Ann.) | 53.4% | 🌪️ High price swings |
| Beta (vs. Market) | 0.24x | 🛡️ Low Sensitivity | |
| Green Days (30d) | 19/30 (63%) | 🟢 Positive trading days | |
| Ownership | Institutional Ownership | 85.40% | 🏛️ Strong institutional backing |
| Short % of Float | 15.66% | 😰 High Bearish Bets |
Right now, CELC stock is trading at $94.00. Technically, things are looking pretty bullish, mainly because the price is holding strong above both its 50-day ($67.24) and 200-day ($38.34) moving averages. This suggests that the stock has been picking up some serious momentum lately.
However, here’s a word of caution: the 14-day Relative Strength Index (RSI) is sitting at 93.5, which is clearly in overbought territory. While the MACD indicator does show a bullish short-term trend, that high RSI could mean we might see some minor pullbacks before the next upward move. It’s always good to be prepared for those dips!
Looking back over the past year, CELC has seen its share price fluctuate between $7.58 and $98.43. This wide range tells us two important things: first, the stock has made a remarkable recovery from its lows, and second, its current price is nearing the higher end of that range. This could imply that major, sudden swings might be less likely unless there’s a significant market event.
Analysts are forecasting some decent growth ahead, with a 1-year target of $129.89 (+38.2%) and an average consensus target of $103.56 (+10.2%). Plus, with a substantial 85.40% institutional ownership and a notable 15.66% short interest, it suggests that while many big players are in, a significant portion of the market is betting against the stock. It’s a mixed bag of investor sentiment!
CELC Stock Price Forecast Chart (Prophet Model)
While we can’t embed a live chart here, imagine a visual representation of Celcuity’s recent average prices alongside a forecasted range. This chart, based on the Prophet model, would illustrate the projected low, average, and high price bands, giving you a clear picture of potential future movements. It’s a great tool for visualizing the trajectory we’re about to discuss in detail.
Also Read – Ondas Holdings Inc. (ONDS) Stock Analysis
Detailed Celcuity (CELC) Price Forecast: Month-by-Month Outlook
Let’s break down the projected price movements for Celcuity (CELC) over the next year. The Prophet model suggests an overall range from approximately $58.66 to $161.32. This table offers a month-by-month view of projected price bands, the potential Return on Investment (ROI) compared to the current price of $94.00, and the resulting model signal for each period.
| Month (Period) | Min. Price | Avg. Price | Max. Price | Potential ROI vs Current ($94.00) | Model Signal |
|---|---|---|---|---|---|
| 2025-11 | $94.23 | $94.23 | $94.23 | ● 0.2% | Hold/Neutral |
| 2025-12 | $58.66 | $71.28 | $81.56 | ▼ -24.2% | Consider Short |
| 2026-01 | $63.82 | $73.21 | $85.59 | ▼ -22.1% | Consider Short |
| 2026-02 | $65.66 | $76.01 | $86.38 | ▼ -19.1% | Consider Short |
| 2026-03 | $65.30 | $77.95 | $88.23 | ▼ -17.1% | Consider Short |
| 2026-04 | $68.24 | $80.69 | $92.69 | ▼ -14.2% | Consider Short |
| 2026-05 | $74.81 | $86.70 | $101.15 | ▼ -7.8% | Consider Short |
| 2026-06 | $79.55 | $92.64 | $109.27 | ▼ -1.4% | Hold/Neutral |
| 2026-07 | $77.60 | $97.87 | $116.65 | ▲ 4.1% | Consider Buy |
| 2026-08 | $81.68 | $103.79 | $129.73 | ▲ 10.4% | Consider Buy |
| 2026-09 | $100.26 | $122.95 | $150.37 | ▲ 30.8% | Consider Buy |
| 2026-10 | $100.73 | $129.89 | $157.99 | ▲ 38.2% | Consider Buy |
| 2026-11 | $104.51 | $129.89 | $161.32 | ▲ 38.2% | Consider Buy |
Looking at the full forecast horizon, from November 2025 through November 2026, the model projects CELC’s price to fluctuate significantly. We could see it move between a low of around $58.66 and a high of $161.32. This range highlights the inherent volatility in the stock.
Interestingly, the projected price range remains relatively consistent over the periods, starting from $94.23 in November 2025 and expanding to $104.51 – $161.32 by November 2026. This implies a fairly stable level of forecast uncertainty, even as the potential upside increases significantly towards the end of the forecast period. It’s important to remember that these models are estimates and depend on current data and assumptions, which can always change. Actual prices are never guaranteed.
Celcuity Inc. (CELC) Company Profile: Biotechnology Innovator
Let’s get to know the company behind the stock. Celcuity Inc. (CELC) is a fascinating player in the Healthcare sector, specifically within the innovative Biotechnology industry. Understanding its core business and structure is fundamental to any investment decision.
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | 4.35 B |
| Employees | 87 |
| Website | https://www.celcuity.com |
Business Overview
Celcuity Inc. is a clinical-stage biotechnology company with a clear mission: developing targeted therapies for various solid tumors in the United States. They’re at the forefront of medical innovation, striving to make a real difference in cancer treatment.
Their flagship drug candidate, Gedatolisib, is particularly noteworthy. It’s designed to selectively target specific Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. This complex targeting mechanism aims to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), as well as those with metastatic castration resistant prostate cancer (mCRPC). It’s a highly specialized and potentially impactful area of research.
Beyond Gedatolisib, Celcuity is also developing its CELsignia diagnostic platform, which could revolutionize how certain cancers are identified and treated. The company previously held a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib, underscoring the potential of their assets. Celcuity Inc. was founded in 2011 and is proudly based in Minneapolis, Minnesota.
Celcuity (CELC) Valuation Snapshot: Market Cap, Enterprise Value & Earnings
When we look at Celcuity Inc.’s valuation, there are a few key figures that stand out. Its market capitalization sits at $4.35 billion, which is a significant size for a biotech firm. What’s interesting is that its enterprise value is slightly lower at $4.21 billion. This difference often signals a strong net cash position, giving the company financial flexibility.
| Metric | Value |
|---|---|
| Market Cap | 4.35 B |
| Enterprise Value | 4.21 B |
| EV/EBITDA (TTM) | -26.46x |
| Next Earnings Date | 2025-11-12 |
This strong net cash position, estimated at approximately $140.00 million, provides a solid cushion for future investments and operational needs. The upcoming earnings report on November 12, 2025, will be a critical event. It will show whether Celcuity Inc.’s business operations can grow into its current valuation, especially given its clinical-stage nature. Essentially, investors are paying for future potential and quality, and that often comes at a premium.
CELC Share Statistics: Insider Ownership, Institutional Holdings & Short Interest
Understanding who owns a company’s shares and how many are available for trading can give us valuable insights into investor confidence and market sentiment. For Celcuity Inc. (CELC), the share statistics paint a compelling picture.
| Metric | Value |
|---|---|
| Shares Outstanding | 46 M |
| Implied Shares Outstanding | 46 M |
| Shares Float | 31 M |
| Insider Ownership | 11.04% |
| Institutional Ownership | 85.40% |
| Shares Short | 6 M |
| Short Ratio (Days To Cover) | 4.00x |
| Short % of Float | 15.66% |
| Shares Short (Prior Month) | 5 M |
| Short Date | 2025-10-31 |
About 32.6% of Celcuity’s shares are closely held by insiders or strategic investors, leaving approximately 31 million shares available for public trading (the float). It’s always a good idea for investors to be aware that companies can issue more shares, which could potentially dilute the value of existing stock.
Executives and major shareholders have a significant stake, holding 11.04% of the company. This is a positive sign, as it helps align their interests directly with those of other shareholders. Even more notable is the substantial institutional ownership, which stands at an impressive 85.40%. This high level of institutional backing often provides a degree of stability and confidence in the stock, as large funds have typically done extensive due diligence.
Now, let’s look at short interest. With 6 million shares currently shorted, representing 15.66% of the float, it suggests that a notable portion of the market is betting against the stock. This indicates a high perceived risk by some investors. Keeping an eye on changes in short interest is crucial; a sharp increase could signal growing bearish sentiment, while a very low short interest during positive news might limit the potential for a “short squeeze.” Overall, the combination of high insider and institutional ownership usually points to strong internal and external confidence, forming a solid foundation for the stock’s stability and potential growth. You can find more details on regulatory filings at the SEC EDGAR database.
Celcuity (CELC) Valuation Ratios: P/E, Price/Book & EV/EBITDA
When we dive into Celcuity (CELC)’s valuation metrics, we see some figures that require careful interpretation, especially given the company’s stage of development. The Trailing P/E ratio is not available (N/A), which is common for companies that are not yet consistently profitable. However, the Forward P/E stands at -29.38x, reflecting anticipated future losses.
| Metric | Value |
|---|---|
| Forward P/E | -29.38x |
| Price/Book (MRQ) | $34.78 |
| EV/EBITDA (TTM) | -26.46x |
From an enterprise value perspective, the EV/EBITDA multiple of -26.46x also points to current unprofitability. For clinical-stage biotechnology companies, negative earnings are not uncommon as they invest heavily in research and development before commercializing products. These valuation metrics provide a comprehensive, albeit complex, view of the company’s current market positioning and future expectations.
Celcuity (CELC) Financial Health: Debt, Liquidity & Cash Flow Analysis
Let’s take a close look at Celcuity (CELC)’s financial health, as the numbers here present a mixed picture that warrants careful attention from investors. While there are some strengths, several areas of concern could pose risks.
| Metric | Value |
|---|---|
| Return on Equity (ROE TTM) | -122.04% |
| Return on Assets (ROA TTM) | -26.60% |
| Debt/Equity (MRQ) | 2.74x |
| Total Cash (MRQ) | 454.98 M |
| Total Debt (MRQ) | 320.34 M |
| Current Ratio (MRQ) | 12.26x |
| Quick Ratio (MRQ) | 11.73x |
| Operating Cash Flow (TTM) | -144.65 M |
| Levered Free Cash Flow (TTM) | -91.55 M |
First, the Return on Equity (ROE) at -122.04% and Return on Assets (ROA) at -26.60% reflect that the company is currently not generating profits from its capital. These negative figures are typical for clinical-stage biotech companies heavily investing in R&D, but they do highlight a lack of current earnings efficiency.
A significant concern is the 2.74x Debt/Equity ratio. With $320.34 million in total debt against $454.98 million in cash, Celcuity has taken on a substantial level of debt to fund its operations and growth. While they have a healthy cash balance, this high leverage could become a burden, especially in a high-interest-rate environment.
Furthermore, a major red flag is the negative operating cash flow of -$144.65 million (TTM). This indicates that the core business activities are currently consuming more cash than they generate. Similarly, levered free cash flow at -$91.55 million shows that after accounting for debt obligations, the company is still burning cash.
On the positive side, Celcuity demonstrates a strong liquidity position. Its Current Ratio of 12.26x and Quick Ratio of 11.73x suggest it can comfortably cover its short-term liabilities with its current assets. This is a crucial strength, providing a buffer against immediate financial pressures.
However, this combination of high debt and negative operating cash flow is a significant risk. It implies the company is burning through cash while also needing to service a large debt load. If this trend isn’t reversed quickly, it could lead to financial distress, making this a high-risk situation that demands close monitoring from investors.
CELC Financial Efficiency: Asset Turnover, Working Capital & ROIC
Assessing Celcuity (CELC)’s financial efficiency reveals some areas that could use improvement, particularly regarding asset utilization. As a clinical-stage biotech, these figures often reflect heavy investment in non-revenue-generating assets like R&D and clinical trials.
| Metric | Value |
|---|---|
| Asset Turnover (TTM) | 0.00x |
| Working Capital Turnover (TTM) | 0.00x |
| Current Ratio (MRQ) | 12.26x |
| Return on Invested Capital (ROIC TTM) | -76.27% |
Celcuity’s Asset Turnover of 0.00x suggests that it’s currently generating virtually no revenue per dollar of assets. This indicates very low efficiency in asset utilization, which is expected for a company without commercialized products. Similarly, the Working Capital Turnover of 0.00x highlights a concerning use of short-term assets to support sales, again due to the lack of revenue.
Despite these low turnover figures, the company’s Current Ratio of 12.26x signals excellent liquidity, meaning it has plenty of short-term assets to cover its short-term liabilities. This robust liquidity is critical for a company in its development phase.
The Return on Invested Capital (ROIC) at -76.27% points to lower capital efficiency. It shows that Celcuity is not yet effectively generating returns from the capital invested in its operations. Overall, while Celcuity has strong liquidity, it clearly needs to improve its asset utilization to boost profitability once its products come to market. Investors should always compare these figures with industry peers to get a complete picture of its competitive positioning.
Celcuity (CELC) Profitability & Growth: Margin Analysis and Earnings Power
An in-depth look at Celcuity (CELC)’s margin performance clearly indicates that the company is facing significant pressure on its profitability. As a clinical-stage biotechnology company, this is often the case as substantial investments are made in research and development without immediate product sales.
| Metric | Value |
|---|---|
| Profit Margin (TTM) | 0.00% |
| Operating Margin (TTM) | 0.00% |
| Gross Margin (TTM) | 0.00% |
| EBITDA Margin (TTM) | 0.00% |
| EBITDA (TTM) | -159.27 M |
| Net Income (TTM) | -162.72 M |
All its margin metrics—Gross Margin, Operating Margin, Profit Margin, and EBITDA Margin—are currently at 0.00%. This is because the company is not yet generating significant revenue from commercialized products. Essentially, for every dollar of revenue (which is currently negligible), Celcuity isn’t holding onto any profit.
The company’s EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) stands at -$159.27 million, and its Net Income is -$162.72 million. These negative figures reflect the heavy investment phase the company is in, highlighting its raw earning power (or lack thereof, currently) and how effectively it converts that into bottom-line results.
Moving forward, maintaining steady or improving margins will be absolutely critical once products are commercialized. Celcuity will need to establish strong pricing power and control its operating costs effectively. This will be essential to sustain profitability, especially if revenue growth eventually moderates after initial product launches.
Celcuity (CELC) Dividends & Shareholder Returns: A Closer Look
When evaluating an investment, especially for long-term holders, dividend policies are often a key consideration. For Celcuity Inc. (CELC), the current approach is quite clear.
Dividend Summary & Investor Implications
Based on the available data, Celcuity (CELC) does not currently pay a regular dividend. This isn’t uncommon for clinical-stage biotechnology companies. Instead of distributing earnings to shareholders, the company appears to be prioritizing reinvesting its capital back into the business. This strategy is typically aimed at funding crucial research, development, and clinical trials to accelerate growth and bring new therapies to market.
| Metric | Value |
|---|---|
| Payout Ratio | 0.00% |
| Trailing Dividend Rate | $0.00 |
| Trailing Dividend Yield | 0.00% |
For investors, this means that any returns from CELC stock would primarily come from capital appreciation—the increase in the stock’s price over time. Those looking for income-generating investments might need to look elsewhere, or consider CELC as a growth-oriented play with no current yield.
Celcuity (CELC) Stock Technical Analysis: Trend, Momentum & Key Levels
Let’s dive into the technical side of Celcuity (CELC) stock. The current price is $94.23, and the trend is undeniably bullish, but it’s showing signs of being overheated. The stock has seen a remarkable run, gaining an impressive +29.10% in just 15 days. However, several technical signals suggest we should approach this momentum with a degree of caution. Let’s break down what the charts are telling us so you can position yourself wisely.
Trend Strength – Still Bullish
Celcuity (CELC) is currently trading above its key moving averages, which strongly confirms that the underlying uptrend remains intact. The 20-day Simple Moving Average (SMA) at $81.76 is acting as immediate dynamic support, a good sign for bulls.
What does this mean for traders? As long as CELC holds above the 20-day SMA ($81.76), the bullish momentum could very well continue. However, a rapid rise like this can push the stock quite far from its averages, which naturally increases the risk of a sharp pullback.
Momentum Check – Time to Be Cautious
This is where things get interesting. The 14-day Relative Strength Index (RSI) is flashing a strong overbought signal at 93.5. Historically, when the RSI crosses above the 70-75 threshold, we often see a cooling-off period or a pullback before the next leg up.
At the same time, the MACD histogram is still positive, which confirms that the upward momentum is technically still in play. So, what’s the trading strategy here? Aggressive traders might consider taking some partial profits off the table. More conservative investors should probably wait for the RSI to cool down below 70 before thinking about new positions.
Bollinger Bands – Testing Key Levels
The stock is trading comfortably in the upper half of its Bollinger Bands, specifically between the 20-day SMA and the upper band. This positioning is generally seen as a sign of underlying strength and positive price action.
Here are the key levels to keep a close eye on:
- Resistance: The recent high of $96.10 is the immediate resistance level. A confirmed breakout above this point, especially with strong volume, could propel CELC even higher.
- Support: The 20-day SMA at $81.76 is your first line of defense. If this level breaks, you should expect a test of the next support at $65.66.
Volume Trends – Checking for Conviction
While the stock has been rising impressively, there’s a red flag in the volume data. Trading volume has been declining and is currently below its 20-day average. This lack of conviction is something to be mindful of.
What’s the concern here? Low volume rallies are often prone to sharp reversals. If we don’t see a significant surge in buying interest to truly confirm this upward move, a pullback becomes a much more likely scenario.
Support & Resistance – The Trading Plan
Based on our technical analysis, here’s a potential trading plan for CELC:
- ✅ If CELC holds above $81.76: The bullish trend is likely to continue, with the next target being $96.10.
- ⚠️ If it breaks below $81.76: Expect a dip toward $65.66, which could be a retest of previous support.
- 🛑 A drop below $65.66: This could trigger a deeper correction, potentially all the way down to the 200-day SMA, which currently sits at $38.34.
Final Verdict – Should You Buy, Hold, or Sell?
This is the big question, isn’t it? Here’s our perspective for different types of investors:
- Short-Term Traders: Be very cautious here. The RSI is significantly overbought at 93.5, and volume is weak. It might be wise to consider locking in partial profits near $96.10 and waiting for a better entry point, perhaps closer to the 20-day SMA at $81.76.
- Long-Term Investors: The long-term uptrend remains valid as long as the price stays above the 200-day SMA ($38.34). A pullback to the 50-day SMA ($67.24) area could present a much safer buying opportunity for those looking to accumulate shares.
- New Buyers: We’d advise against chasing this rally right now. It’s better to wait for either a confirmed breakout above $96.10 with strong volume, or patiently wait for a pullback to the $81.76 area, which would offer a more favorable risk/reward entry.
Bottom Line: The technical indicators suggest that the current rally in CELC might be running out of steam in the short term. While the long-term trend still looks bullish, a healthy correction seems plausible before the stock makes its next major move. Trade carefully, always wait for clear confirmations at key levels, and manage your risk.
Bollinger Bands Insight for CELC Stock
While we can’t display the actual chart, imagine the Bollinger Bands tightening or expanding around the price action of CELC. This visual would show how the stock is currently trading within the upper half of its bands, indicating strength. However, an overextended move towards the upper band, especially with declining volume, often signals that a price correction or consolidation might be on the horizon.
Relative Strength Index (RSI) for CELC Stock
The RSI chart would visually confirm the current overbought conditions. A line soaring above the 70-level, currently at 93.5, is a clear sign that buying pressure has been intense and unsustainable in the short term. Traders use this to identify potential reversal points or at least a pause in the uptrend.
Moving Average Convergence Divergence (MACD) for CELC Stock
The MACD chart would show the relationship between two moving averages of CELC’s price, along with a histogram. Currently, the MACD indicator is positive (0.77), with the MACD line above the signal line, and the histogram bars are positive. This confirms the short-term bullish momentum, despite the RSI suggesting caution. A crossover could indicate a shift in trend.
Historical Price & Volume Trends for CELC Stock
A historical chart would display Celcuity’s closing price and trading volume over time, typically with a 20-day average volume overlay. This visual would allow you to quickly assess past price movements, periods of high or low volume, and how current trends compare to historical patterns. It’s an essential tool for understanding the stock’s long-term behavior.
Celcuity (CELC) Historical Performance: Recent Trading Data
Let’s take a closer look at Celcuity (CELC)’s recent stock performance to understand its trajectory. Over the last 15 trading days, specifically from November 05, 2025, to November 19, 2025, CELC delivered a strong return of +26.33%. This indicates robust positive momentum in the very recent past.
During this period, the stock traded within a range of $71.06 to $96.10, showcasing significant price action. The average daily trading volume during these 15 days was 947,520 shares, reflecting active investor interest.
Detailed CELC Recent Trading Data
Here’s a day-by-day breakdown of Celcuity’s recent trading activity, giving you a granular view of its price movements and volume.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| 2025-11-19 | $92.21 | $94.70 | $91.41 | $94.23 | 751,600 |
| 2025-11-18 | $88.00 | $93.36 | $86.56 | $91.60 | 1,426,900 |
| 2025-11-17 | $90.40 | $96.10 | $89.65 | $92.23 | 1,621,700 |
| 2025-11-16 | $84.12 | $94.06 | $84.12 | $92.68 | 1,312,100 |
| 2025-11-15 | $84.12 | $94.06 | $84.12 | $92.68 | 1,312,100 |
| 2025-11-14 | $84.12 | $94.06 | $84.12 | $92.68 | 1,312,100 |
| 2025-11-13 | $85.15 | $87.74 | $82.07 | $86.00 | 1,200,800 |
| 2025-11-12 | $79.24 | $85.23 | $79.24 | $85.15 | 1,330,000 |
| 2025-11-11 | $76.05 | $79.47 | $76.05 | $79.17 | 575,900 |
| 2025-11-10 | $75.88 | $77.54 | $74.01 | $76.70 | 431,600 |
| 2025-11-09 | $74.20 | $74.94 | $72.05 | $74.52 | 448,000 |
| 2025-11-08 | $74.20 | $74.94 | $72.05 | $74.52 | 448,000 |
| 2025-11-07 | $74.20 | $74.94 | $72.05 | $74.52 | 448,000 |
| 2025-11-06 | $74.55 | $75.02 | $72.96 | $74.20 | 637,800 |
| 2025-11-05 | $73.81 | $74.79 | $71.06 | $74.59 | 956,200 |
CELC Stock Price Statistics: Volatility, Beta & Moving Averages
Understanding the statistical characteristics of a stock’s price movements can give investors a clearer picture of its risk and behavior relative to the broader market. Let’s look at Celcuity (CELC)’s key price statistics.
| Metric | Value |
|---|---|
| 52 Week High | $98.43 |
| 52 Week Low | $7.58 |
| 50 Day MA | $63.59 |
| 200 Day MA | $30.44 |
| Beta | 0.24x |
| Volatility (30d Ann.) | 53.4% |
Over the past year, Celcuity’s stock has experienced quite a journey, ranging from a high of $98.43 to a low of $7.58. This wide gap tells us that the stock has been subject to significant fluctuations, likely driven by market sentiment, company-specific news, and general biotechnology sector dynamics.
Currently, the 50-day moving average at $63.59 is trading above the 200-day moving average of $30.44. This configuration, often referred to as a ‘golden cross,’ is generally considered a bullish signal, suggesting positive long-term momentum is building.
With a beta of 0.24x, CELC tends to be significantly less volatile than the broader market, moving approximately 76% less than the overall market. However, don’t let that low beta fool you into thinking it’s a calm ride! The stock also exhibits a high 30-day annualized volatility of 53.4%, indicating that while it’s less sensitive to overall market swings, it still sees frequent and substantial price movements on its own. For investors, this means there’s potential for gains, but also an elevated level of downside risk, demanding careful position sizing and entry timing.
Celcuity (CELC) Quarterly Earnings Performance: Revenue & Net Income
Let’s review Celcuity (CELC)’s recent quarterly financial performance. As a clinical-stage biotechnology company, its financial results often look different from those of revenue-generating businesses. The latest quarter shows a continued focus on development rather than commercialized sales.
Celcuity’s most recent quarterly report shows revenue of $0 and a net loss of -$43.80 million. This zero revenue figure is typical for a company primarily engaged in research and development, without products yet on the market.
CELC Recent Quarterly Results Breakdown
Here’s a look at Celcuity’s financial performance over the last four quarters, highlighting its revenue, net income, and EPS.
| Quarter | Revenue | Net Income | EPS | Gross Margin |
|---|---|---|---|---|
| 2025-Q3 | 0 | -43.80 M | -0.92x | N/A |
| 2025-Q2 | 0 | -45.27 M | -1.04x | N/A |
| 2025-Q1 | 0 | -37.00 M | -0.86x | N/A |
| 2024-Q4 | 0 | -36.65 M | -0.85x | N/A |
CELC Growth Metrics: Net Income Trends
While revenue is currently at zero, tracking the net income trend for a clinical-stage company can still offer insights into its operational burn rate and efficiency.
| Metric | Value |
|---|---|
| QoQ Net Income Growth | -3.2% |
The quarter-over-quarter net income growth shows a slight decrease of -3.2%, indicating a slightly larger loss compared to the previous quarter. This is typical as R&D expenses can fluctuate based on trial stages and development milestones.
Upcoming Celcuity (CELC) Earnings Report & Call
Keeping an eye on upcoming earnings dates is crucial for any investor. These events can often lead to significant stock price movements as new financial data and outlooks are released.
| Event | Date/Time |
|---|---|
| Next Report | November 13, 2025 |
| Earnings Call | November 13, 2025 at 03:00 AM ET |
Investors should mark their calendars for November 13, 2025, when Celcuity Inc. is scheduled to release its next earnings report and host its earnings call. This will be a key opportunity to gain updated insights into the company’s financial performance and strategic direction.
Celcuity (CELC) Short Selling Insights: Bearish Bets on the Stock
Short selling activity can be a powerful indicator of market sentiment, often reflecting a bearish outlook from a segment of investors. Let’s delve into the short interest data for Celcuity (CELC) and what it might imply.
| Metric | Value |
|---|---|
| Shares Short | 6 M |
| Short Ratio (Days To Cover) | 4.00x |
| Short % of Float | 15.66% |
| Shares Short (Prior Month) | 5 M |
| Short Date | 2025-10-31 |
Currently, there are 6 million shares of CELC worth of short interest, and the short ratio, also known as “days to cover,” stands at 4.0x. This ratio means that, at the stock’s recent average trading volume, it would take approximately four days for all short positions to be covered. This moderate level suggests a balance between bearish bets and the market’s capacity to absorb them without extreme volatility.
However, with 15.66% of the public float sold short, it indicates a significant bearish conviction from a portion of the market. What’s more, this level has recently increased from 5 million shares shorted in the prior month, suggesting a growing negative sentiment. Investors should be acutely aware of potential volatility spikes, which could be triggered by positive news events forcing short sellers to cover their positions, leading to a “short squeeze.” It’s a dynamic to watch closely.
Celcuity (CELC) Risk Analysis: Volatility, Drawdown & Risk-Adjusted Returns
Understanding the risk profile of an investment like Celcuity (CELC) is just as crucial as assessing its growth potential. This section breaks down various risk metrics to give you a comprehensive picture of what you might be getting into.
| Metric | Value |
|---|---|
| Volatility (Annualized) | 77.4% |
| Value at Risk (5%) | -5.37% |
| Value at Risk (1%) | -9.16% |
| Sharpe Ratio | 0.47x |
| Sortino Ratio | 0.95x |
| Maximum Drawdown | -85.64% |
| Skewness | 14.55x |
| Kurtosis | 473.09x |
Celcuity’s risk profile indicates high volatility, with an annualized volatility of 77.4%. This figure signals a high level of investment risk, meaning the stock price can experience substantial swings in either direction.
The Sharpe ratio of 0.47x suggests mixed risk-adjusted returns. While positive, it indicates that the return generated per unit of risk is moderate. The Sortino ratio of 0.95x, which focuses specifically on downside risk, provides additional insight into its performance when accounting for negative fluctuations.
Perhaps most striking is the maximum drawdown of -85.64%. This metric reveals that, at some point, the stock experienced a very significant decline from its peak, indicating substantial downside risk during adverse market conditions.
The Value at Risk (VaR) at a 5% confidence level shows a potential loss of -5.37% in the worst 5% of scenarios, while at a 1% confidence level, the potential loss increases to -9.16%. These VaR figures help quantify potential losses over a specific period.
Finally, the high Skewness (14.55x) and Kurtosis (473.09x) values suggest that the stock’s returns distribution has a long right tail (more frequent small gains, but also potential for extreme positive events) and heavier tails than a normal distribution, implying a higher likelihood of extreme outcomes (both positive and negative). Investors absolutely need to consider these risk metrics in conjunction with their personal risk tolerance and overall investment objectives.
Celcuity (CELC) Sentiment Analysis: What the Market is Saying
Market sentiment can significantly influence stock prices, often reflecting the collective mood of investors. For Celcuity (CELC), our current sentiment a cautiously positive outlook, which is quite interesting given some of the financial challenges.
| Metric | Value |
|---|---|
| Composite Sentiment Score | 0.64x |
| Sentiment Classification | Positive |
| Sentiment Confidence | 45.4% |
| News Sentiment | Positive (0.12x) |
| Analyst Sentiment | Positive (0.80x) |
| Options Sentiment | Positive (0.72x) |
| Put/Call Ratio | 0.14x |
The composite sentiment score for CELC is 0.64x, classifying the overall market sentiment as “Positive.” However, it’s important to note that the confidence level for this sentiment is moderate at 45.4%. This positive sentiment isn’t just a hunch; it’s derived from multiple data sources, including recent news coverage, analyst recommendations, and activity in the options market.
Breaking down the components, news analysis shows a Positive sentiment at 0.12x. Analyst consensus is notably Positive at 0.80x, indicating strong backing from Wall Street. The options market sentiment also reflects a Positive outlook at 0.72x, further supported by a low Put/Call Ratio of 0.14x, which suggests relatively fewer bearish bets via put options. These sentiment indicators should always be considered alongside a thorough fundamental and technical analysis to form a truly comprehensive investment perspective.
Celcuity (CELC) Peer Comparison: How It Stacks Up Against Competitors
To truly understand Celcuity (CELC)’s position in the market, it’s essential to see how it measures up against its peers in the biotechnology industry. We’re comparing CELC to ACLX, LEGN, and TGTX, all notable players in the space.
Celcuity, with its $4.35 billion market cap, currently stands as the smallest among this group, with ACLX at $5.18 billion, LEGN at $5.08 billion, and TGTX at $4.83 billion. This size difference can impact everything from market influence to access to capital.
When it comes to profitability, CELC faces significant challenges. It currently has negative earnings, making a meaningful P/E ratio analysis difficult. In contrast, ACLX and LEGN also report negative P/E ratios, indicating current losses, but their numbers are somewhat different. TGTX, on the other hand, shows a positive P/E of 10.99, reflecting a profitable and potentially more mature business.
Celcuity’s 0.0% net margin highlights its current unprofitability, especially when compared to TGTX’s impressive 84.1% net margin. LEGN also faces significant losses with a -26.4% net margin. Similarly, CELC’s negative -1.22% ROE reflects its current unprofitability.
Perhaps the most striking difference is in debt levels. Celcuity’s high 274 Debt-to-Equity ratio indicates significant financial leverage. This contrasts sharply with ACLX (11.75), LEGN (40.57), and TGTX (41.92), which all maintain considerably lower debt levels, suggesting a potentially more conservative financial approach among its peers.
| Metric | CELC | ACLX | LEGN | TGTX |
|---|---|---|---|---|
| Market Cap | $4.35B | $5.18B | $5.08B | $4.83B |
| P/E Ratio | -29.38 | -39.81 | -41.09 | 10.99 |
| Revenue Growth | N/A | -81.00% | 70.00% | 92.80% |
| Net Margin | 0.00% | 0.00% | -26.37% | 84.13% |
| EPS | -3.68 | -3.93 | -1.28 | 2.77 |
| ROE | -1.22% | -47.18% | -22.53% | 1.12% |
| Debt-to-Equity | 274 | 11.75 | 40.57 | 41.92 |
| Dividend Yield | 0.00% | 0.00% | 0.00% | 0.00% |
| 52-Week Range | 7.57 – 98.43 | 47.86 – 96.39 | 27.34 – 45.30 | 25.28 – 46.48 |
CELC Insider Transactions: What Company Insiders Are Doing
Insider transactions often provide valuable clues about a company’s prospects, as those closest to the business are either buying or selling shares. Over the last three months, the insider transaction data for Celcuity (CELC) reveals a predominantly bullish trend, with 7 buys versus 3 sells.
This overall buying activity is further reinforced by discretionary market activity, showing 4 open-market purchases versus 0 sales. This suggests that insiders perceive value in the stock at its current prices and are willing to put their own money on the line.
The recent shift towards buying interest, with insiders becoming more active on the purchase side, is a strong positive signal. The predominance of insider buying, particularly through open-market transactions, implies that those with the deepest knowledge of the company are increasing their financial commitment. This can create a solid foundation for the stock’s stability and potential growth.
| Insider Name | Type | Shares Changed | Price | Shares After | Transaction Date | Filing Date |
|---|---|---|---|---|---|---|
| NIGON RICHARD | SELL (Unknown) [X] | -3,245 | ~$57.43 | N/A | 2025-09-15 | |
| NIGON RICHARD | SELL (Unknown) [X] | -4,672 | ~$57.43 | N/A | 2025-09-15 | |
| NIGON RICHARD | BUY (Unknown) [X] | +3,245 | $7.56 | 109,010 | 2025-09-11 | 2025-09-15 |
| NIGON RICHARD | BUY (Unknown) [X] | +4,672 | $7.56 | 105,765 | 2025-09-11 | 2025-09-15 |
| BAKER JULIAN | BUY (Purchase) [P] | +4,212 | $58.02 | 7,211,484 | 2025-09-08 | 2025-09-10 |
| BAKER JULIAN | BUY (Purchase) [P] | +388 | $58.02 | 704,308 | 2025-09-08 | 2025-09-10 |
| BAKER JULIAN | BUY (Purchase) [P] | +151,524 | $56.22 | 7,207,272 | 2025-09-08 | 2025-09-10 |
| BAKER JULIAN | BUY (Purchase) [P] | +13,976 | $56.22 | 703,920 | 2025-09-08 | 2025-09-10 |
| Sullivan Brian F. | SELL (Unknown) [X] | -104,340 | ~$53.58 | * | N/A | 2025-09-04 |
| Sullivan Brian F. | BUY (Unknown) [X] | +104,340 | $8.05 | 1,370,199 | 2025-09-02 | 2025-09-04 |
Key Risk Factors for Celcuity (CELC) Investors
Every investment comes with its own set of risks, and Celcuity (CELC) is no exception. While we’ve highlighted potential upsides, it’s crucial to be aware of the factors that could negatively impact your investment. This section outlines some of the key risks identified through our analysis.
Here are some important risk factors to consider:
- ⚠️ Overbought RSI: The 14-day Relative Strength Index (RSI) is currently very high at 93.5. This suggests that the stock may be overbought, potentially indicating a heightened risk of a near-term price pullback or correction.
- ⚠️ High Debt-to-Equity Ratio: Celcuity carries a high Debt-to-Equity ratio of 2.74x. This significant financial leverage indicates that the company relies heavily on debt to fund its operations and growth, which can increase financial risk, especially in a rising interest rate environment.
- ⚠️ General Market Fluctuations: Like all stocks, CELC is susceptible to broader market fluctuations and economic conditions. The Healthcare sector, particularly biotechnology, can be sensitive to regulatory changes, funding environments, and overall investor sentiment.
Investors should carefully weigh these risk metrics against their personal risk tolerance and investment objectives before making any decisions.
Wall Street Consensus: Celcuity (CELC) Analyst Ratings & Price Targets
What do the experts on Wall Street think about Celcuity (CELC)? It’s always helpful to gauge the sentiment from professional analysts who cover the stock closely. The consensus among analysts is quite optimistic.
| Metric | Value |
|---|---|
| Recommendation | Strong Buy |
| Mean Target Price | $103.56 |
| High Target Price | $115.00 |
| Low Target Price | $94.00 |
| Number of Analyst Opinions | 9 |
The average recommendation for CELC is a resounding “Strong Buy.” This consensus is based on the opinions of 9 analysts who cover the company. Their average price target is $103.56, with a range spanning from a low of $94.00 to a high of $115.00.
Based on this mean target of $103.56, analysts are implying a potential upside of approximately +10.2% from the current stock price of $94.00. This reflects an overall positive sentiment from the analyst community regarding Celcuity’s future outlook and potential for growth.
Latest News & Developments for Celcuity Inc. (CELC)
Staying informed about the latest news and developments is vital for any investor. Here are some recent headlines concerning Celcuity Inc. (CELC), which can impact its stock performance and investor sentiment.
- Celcuity (CELC) Is Up 7.6% After FDA Accepts Gedatolisib Application for Expedited Review – What’s Changed
Publisher: Simply Wall St. | Published: 2025-11-19T03:19:33Z - Block upgraded, Dell downgraded: Wall Street’s top analyst calls
Publisher: TipRanks | Published: 2025-11-18T14:35:30Z - Celcuity Inc (CELC) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
Publisher: GuruFocus.com | Published: 2025-11-13T05:01:47Z - Assessing Celcuity (CELC): What a 71x Price-to-Book Ratio Says About Valuation
Publisher: Simply Wall St. | Published: 2025-11-10T02:10:50Z - Celcuity Eyeing Cancer Treatment Riddle. Stock Flies 534% This Year.
Publisher: Investor’s Business Daily | Published: 2025-11-06T15:03:33Z
Celcuity (CELC) Stock: Our Final Thoughts and Investment Outlook
Bringing all our analysis together, Celcuity (CELC) presents a complex but potentially exciting picture for investors. On the technical front, the stock is showing strong bullish momentum, trading well above its key moving averages. However, the significantly overbought RSI at 93.5 suggests that a short-term pullback is a distinct possibility, urging caution for aggressive traders.
Short-Term Technical Snapshot
- ▲ Overall Technical Sentiment: Strong Bullish
- ▲ Price Trend vs MAs: Bullish (above SMA50/200)
- ⚠️ Momentum (RSI): Overbought (93.5)
- 📊 Support / Resistance (30d): ~$64.61 / ~$96.10
Longer-Term Fundamental & Forecast Outlook
- ▲ 1-Year Avg. Forecast: ~+38.2% average change to ≈$129.89
- ● Fundamental Health: Assessment Incomplete (ROE: -122.04%, D/E: 2.74x). The high debt and negative cash flow are significant concerns, though offset by strong liquidity.
- ● Valuation Snapshot: Appears Moderate (Fwd P/E: -29.38x). This reflects its current clinical stage and expected future losses.
- ● Recent Growth (YoY): N/A (Revenue: N/A, Earnings: N/A), due to being a clinical-stage company.
- ▲ Analyst Consensus: Strong Buy (Target: $103.56)
Overall Assessment & Outlook
Overall, Celcuity (CELC) combines a strong bullish technical picture with a fundamental health assessment that signals caution due to its high debt and negative cash flow, typical for a developmental biotech. Its current valuation appears moderate when considering its future potential, despite negative forward P/E. Our models project a 1-year path indicating potential upside of around +38.2%, targeting approximately $129.89.
Investors should carefully weigh these factors against their personal risk tolerance and investment timeline. While the long-term potential in the biotechnology space is considerable, the short-term technical warnings and fundamental financial risks cannot be ignored. Always conduct thorough independent research and consult with a qualified financial advisor before making any investment decisions.
Frequently Asked Questions (FAQ) About Celcuity (CELC) Stock
What is the CELC stock price prediction for the next year (2025-2026)?
Based on current models, the average 1-year price forecast for CELC is approximately $129.89. This represents a potential +38.2% change from the recent price of $94.00. Remember, this is a model-driven estimate, not a guarantee, and actual prices will fluctuate based on numerous market factors.
Will CELC stock go up or down?
The 1-year forecast model suggests the price might show strong gains on average (+38.2% potential). However, the short-term direction is highly uncertain and heavily influenced by prevailing market sentiment (currently ‘Strong Bullish’), breaking news, and overall economic conditions. Technical indicators, particularly the overbought RSI, suggest caution or a potential for a short-term pullback.
Is CELC stock a good investment right now?
Determining if CELC is a ‘good buy’ requires evaluating multiple factors. Technical sentiment is ‘Strong Bullish’, while the 1-year forecast suggests +38.2% potential. However, the RSI indicates overbought conditions (RSI: 93.5), suggesting caution. Additionally, specific risk factors for CELC were identified, including high debt. Align these factors with your personal investment strategy and risk tolerance.
How volatile is CELC stock?
Based on the recent 30-day price action, CELC’s annualized volatility is approximately 53.4%. This level is currently considered high, indicating a significant degree of recent price fluctuation. This aligns with its Beta of 0.24x, which suggests it is less sensitive to broader market movements but can still experience large swings. Higher volatility means larger potential price swings (both up and down).
What are the key upcoming events for CELC?
The next major upcoming event for Celcuity (CELC) is its earnings report and call scheduled for November 13, 2025. Beyond these, investors should monitor macroeconomic shifts, competitive actions within the biotechnology sector, and any major corporate announcements regarding clinical trial progress or regulatory approvals.
What does CELC’s liquidity position reveal about its financial health?
CELC’s financial health includes a strong Current Ratio of 12.26x and a Quick Ratio of 11.73x, suggesting it can comfortably cover its short-term liabilities. However, its operating cash flow of -$144.65 million and levered free cash flow of -$91.55 million indicate the company is currently burning cash. While liquidity is strong, the negative cash flow warrants careful monitoring.
Pingback: Discovery Silver Corp. (DSVSF) Stock Analysis: Price Forecast, Technicals & Investment Outlook - Stockdunia